Project Grant R21AR083766
Award Date 8/1/25
Completion Date 7/30/27
Dollars Obligated $370K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19140, USA
Similar Awards
- This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to understand the plasticity of melanocyte stem cells (MCSCs) and mature melanocytes in adult hair follicles. The $1,917,396 award to New York University School of Medicine will support live-imaging techniques to delineate the fate decision process of MCSCs, from partial differentiation...
- This $250,396 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support research to identify differences in DNA regulatory elements that control gene expression in skin cells from individuals of different ancestral backgrounds. The research team at the Icahn School of Medicine at Mount Sinai will utilize advanced genomic techniques, including...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $407,770 Project Grant (CFDA # 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The grant supports an exploratory study on the role of NKG2D signaling in T cell trafficking and its implications for vitiligo and melanoma. The study aims to define the underlying signaling pathways through which...
- This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), is supporting research to discover and develop novel small molecule therapeutics for vitiligo. The $306,278 award to Aohbio Corporation, located in Athens, OH, aims to investigate the efficacy of the lead compound COB-187 in inhibiting interferon-gamma induced CXCL10 expression by human...
- This federal Project Grant award, valued at $1,826,181.00 and effective from September 1, 2025 to August 31, 2028, was issued by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research grant program (CFDA 93.846). The grant aims to comprehensively understand the contribution of Langerhans cells, resident cells in the epidermis, to chronic itch associated with various skin and systemic diseases. The research...
- This Project Grant award, totaling $176,148.00 and effective from April 1, 2025 to March 31, 2030, was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846). The funding supports a research project led by Dr. Maxime Kinet at the University of California, San Francisco (UCSF) that aims to elucidate the mechanisms by which PI16-expressing fibroblasts, a...
- This $224,100 federal Project Grant award, funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support research to identify epigenetic factors that control the longevity of epidermal stem cells in adult skin. The project aims to elucidate the functional role of epigenetic regulators and their corresponding histone modifications in maintaining the longevity of hair...
- This federal Project Grant award of $390,913 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support a mechanistic investigation into the role of the protein SERPINB3 in the pathogenesis of psoriasis. The research project, being conducted by Arizona State University, will explore the hypothesis that the misprocessing of SERPINB3 is the initiating factor in the...
- This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846) provides $249,000.00 to the University of Massachusetts Medical School to develop a therapeutic platform using small interfering RNA (siRNA) for gene silencing in the treatment of skin diseases. The project aims to evaluate the safety and efficacy of silencing the JAK1 immune mediator in...
- This federal Project Grant award, valued at $1,901,310.00 and provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), supports research under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The research project aims to investigate how skin inflammation drives the development of psoriatic arthritis, a condition that affects up to one-third of individuals with psoriasis. The project will use a novel mouse model to study the...